Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | May 2024
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. 2023 saw the label expansion of Keytruda into the resectable early-stage NSCLC space, gaining FDA approval for adjuvant use in January and for perioperative (neoadjuvant then adjuvant) use in October. The metastatic setting also saw new entrants with the approval of the biomarker-targeted agents Braftovi plus Mektovi for BRAF-mutated NSCLC in October and Augtyro for NSCLC with ROS1 rearrangements in November. These approvals, against the backdrop of numerous existing agents in the NSCLC space, provide medical oncologists with an ever-increasing array of treatment options.
Questions answered
- What are the treatment rates for metastatic NSCLC in the various settings and lines of therapy?
- What are the rates of testing for different biomarkers, and what is the uptake of key biomarker-driven therapies?
- How are new therapies for metastatic NSCLC performing relative to existing therapies?
- What do surveyed physicians consider the main drivers of and key obstacles to the uptake of select therapies?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 U.S. medical oncologists
Key drugs covered: Alecensa, Enhertu, Gavreto, Imfinzi, Imjudo, Keytruda, Krazati, Libtayo, Lumakras, Opdivo, Retevmo, Rybrevant, Tabrecta, Tagrisso, Tecentriq, Tepmetko, Yervoy
